|
1
|
Missaoui N, Hmissa S, Trabelsi A, Frappart
L, Mokni M and Korbi S: Cervix cancer in Tunisia: Clinical and
pathological study. Asian Pac J Cancer Prev. 11:235–238.
2010.PubMed/NCBI
|
|
2
|
Feng Y, Cao T, Wang Y, Huang H, Xie Y and
Liu J: Neoadjuvant chemotherapy followed by conization to spare
fertility in cases of locally advanced cervical cancer: A case
report and review of the literature. Mol Clin Oncol. 5:411–416.
2016.PubMed/NCBI
|
|
3
|
Qin AQ, Liang ZG, Ye JX, Li J, Wang JL,
Chen CX and Song HL: Significant efficacy of additional concurrent
chemotherapy with radiotherapy for postoperative cervical cancer
with risk factors: A systematic review and meta-analysis. Asian Pac
J Cancer Prev. 17:3945–3951. 2016.PubMed/NCBI
|
|
4
|
Gambari R, Brognara E, Spandidos DA and
Fabbri E: Targeting oncomiRNAs and mimicking tumor suppressor
miRNAs: New trends in the development of miRNA therapeutic
strategies in oncology (Review). Int J Oncol. 49:5–32.
2016.PubMed/NCBI
|
|
5
|
Zeng K, Zheng W, Mo X, Liu F, Li M, Liu Z,
Zhang W and Hu X: Dysregulated microRNAs involved in the
progression of cervical neoplasm. Arch Gynecol Obstet. 292:905–913.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shen Y, Wang P, Li Y, Ye F, Wang F, Wan X,
Cheng X, Lu W and Xie X: miR-375 is upregulated in acquired
paclitaxel resistance in cervical cancer. Br J Cancer. 109:92–99.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pedroza-Torres A, López-Urrutia E,
Garcia-Castillo V, Jacobo-Herrera N, Herrera LA, Peralta-Zaragoza
O, López-Camarillo C, De Leon DC, Fernández-Retana J, Cerna-Cortés
JF and Pérez-Plasencia C: MicroRNAs in cervical cancer: Evidences
for a miRNA profile deregulated by HPV and its impact on
radio-resistance. Molecules. 19:6263–6281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu S, Cheng X, Zheng H and Xie R:
Clinical efficacy and safety of paclitaxel plus cisplatin
neoadjuvant treatment on locally advanced cervical cancer. Zhongguo
Linchuang Yaolixue Zazhi. 31:432–434. 2015.(In Chinese).
|
|
9
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Deftereos G, Corrie SR, Feng Q, Morihara
J, Stern J, Hawes SE and Kiviat NB: Expression of mir-21 and
mir-143 in cervical specimens ranging from histologically normal
through to invasive cervical cancer. PLoS One. 6:e284232011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lui WO, Pourmand N, Patterson BK and Fire
A: Patterns of known and novel small RNAs in human cervical cancer.
Cancer Res. 67:6031–6043. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang X, Tang S, Le SY, Lu R, Rader JS,
Meyers C and Zheng ZM: Aberrant expression of oncogenic and
tumor-suppressive microRNAs in cervical cancer is required for
cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang XM, Xu J, Cheng ZQ, Peng QZ, Hu JT,
Gao LK, Zhang SF and Jin HT: Study on effects of microRNA-21
antisense oligonucleotide in vivo and in vitro on bionomics of
human cervical squamous carcinoma cell lines SiHa. Zhonghua Bing Li
Xue Za Zhi. 41:254–259. 2012.(In Chinese). PubMed/NCBI
|
|
14
|
Zhu W and Xu B: MicroRNA-21 identified as
predictor of cancer outcome: A meta-analysis. PLoS One.
9:e1033732014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Y, Zhu Y, Lv P and Li L: Targeting
miR-21 with AS-miR-21 suppresses aggressive growth of human tongue
squamous cell carcinoma in vivo. Int J Clin Exp Pathol.
8:4773–4781. 2015.PubMed/NCBI
|
|
16
|
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT,
Liu B and Bao JK: Programmed cell death pathways in cancer: A
review of apoptosis, autophagy and programmed necrosis. Cell
Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeestraten EC, Benard A, Reimers MS,
Schouten PC, Liefers GJ, van de Velde CJ and Kuppen PJ: The
prognostic value of the apoptosis pathway in colorectal cancer: A
review of the literature on biomarkers identified by
immunohistochemistry. Biomark Cancer. 5:13–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Y, Yang H, Barnie PA, Yang P, Su Z,
Chen J, Jiao Z, Lu L, Wang S and Xu H: The expression of Toll-like
receptor 8 and its relationship with VEGF and Bcl-2 in cervical
cancer. Int J Med Sci. 11:608–613. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fernandes AT, Rocha NP, Vendrame E,
Russomano F, Grinsztejn BJ, Friedman RK, Pinto AC, Klumb EM, Avvad
E, Macedo J, et al: Polymorphism in apoptotic BAX (−248G>A) gene
but not in anti-apoptotic BCL2 (−938C>A) gene and its protein
and mRNA expression are associated with cervical intraepithelial
neoplasia. Apoptosis. 20:1347–1357. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang Y, He Y and Li J: MicroRNA-21: A
central regulator of fibrotic diseases via various targets. Curr
Pharm Des. 21:2236–2242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yao Q, Xu H, Zhang QQ, Zhou H and Qu LH:
MicroRNA-21 promotes cell proliferation and down-regulates the
expression of programmed cell death 4 (PDCD4) in HeLa cervical
carcinoma cells. Biochem Biophys Res Commun. 388:539–542. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lankat-Buttgereit B and Göke R: The tumour
suppressor Pdcd4: Recent advances in the elucidation of function
and regulation. Biol Cell. 101:309–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Asangani IA, Rasheed SA, Nikolova DA,
Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and
stimulates invasion, intravasation and metastasis in colorectal
cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen Y, Liu W, Chao T, Zhang Y, Yan X,
Gong Y, Qiang B, Yuan J, Sun M and Peng X: MicroRNA-21
down-regulates the expression of tumor suppressor PDCD4 in human
glioblastoma cell T98G. Cancer Lett. 272:197–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Roy K, Singh N, Kanwar RK and Kanwar JR:
Survivin modulators: An updated patent review (2011–2015). Recent
Pat Anticancer Drug Discov. 11:152–169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu D, Yin X and Xiao Q: Expressions of
PTEN and Survivin in the progression of cervical neoplasia and
their clinical significances. Zhongguo Fuyou Baojian. 28:4721–4724.
2013.(In Chinese).
|
|
27
|
Hu Q and Liu K: The expression of CIP2A
and c-Myc and their correlation analysis in cervical carcinoma
tissues. Zhong Qing Yi Xue Bian Ji Bu. 44:1072–1074. 2015.(In
Chinese).
|
|
28
|
Wang Y and Dai B: PTEN genomic deletion
defines favorable prognostic biomarkers in localized prostate
cancer: A systematic review and meta-analysis. Int J Clin Exp Med.
8:5430–5437. 2015.PubMed/NCBI
|
|
29
|
Wang LL, Hao S, Zhang S, Guo LJ, Hu CY,
Zhang G, Gao B, Zhao JJ, Jiang Y, Tian WG, et al: PTEN/PI3K/AKT
protein expression is related to clinicopathologic features and
prognosis in breast cancer with axillary lymph node metastases. Hum
Pathol pii. S0046–8177. 2016.
|
|
30
|
Bu L, Ma Y and Shi S: Expressions of CD31,
CD105 and PTEN in cervical cancer and the clinical pathological
significance. Zhongguo Fuyou Baojian. 30:1446–1449. 2015.
|
|
31
|
Rizvi MM, Alam MS, Mehdi SJ, Ali A and
Batra S: Allelic loss of 10q23.3, the PTEN gene locus in cervical
carcinoma from Northern Indian population. Pathol Oncol Res.
18:309–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qi Q, Ling Y, Zhu M, Zhou L, Wan M, Bao Y
and Liu Y: Promoter region methylation and loss of protein
expression of PTEN and significance in cervical cancer. Biomed Rep.
2:653–658. 2014.PubMed/NCBI
|
|
33
|
Lu D, Qian J, Yin X, Xiao Q, Wang C and
Zeng Y: Expression of PTEN and survivin in cervical cancer:
Promising biological markers for early diagnosis and prognostic
evaluation. Br J Biomed Sci. 69:143–146. 2012.PubMed/NCBI
|
|
34
|
Schwarz JK, Payton JE, Rashmi R, Xiang T,
Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS and
Grigsby PW: Pathway-specific analysis of gene expression data
identifies the PI3K/Akt pathway as a novel therapeutic target in
cervical cancer. Clin Cancer Res. 18:1464–1471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tao YJ, Li YJ, Zheng W, Zhao JJ, Guo MM,
Zhou Y, Qin NL, Zheng J and Xu L: Antisense oligonucleotides
against microRNA-21 reduced the proliferation and migration of
human colon carcinoma cells. Cancer Cell Int. 15:772015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu J, Zhang W, Lv Q and Zhu D:
Overexpression of miR-21 promotes the proliferation and migration
of cervical cancer cells via the inhibition of PTEN. Oncol Rep.
33:3108–3116. 2015.PubMed/NCBI
|
|
37
|
Eskander RN and Tewari KS: Chemotherapy in
the treatment of metastatic, persistent, and recurrent cervical
cancer. Curr Opin Obstet Gynecol. 26:314–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
